 Allakos Inc NASDAQ: ALLK is trading significantly lower Wednesday after the company announced ENIGMA 2 and KRYPTOS studies did not achieve statistical significance on the patient reported symptomatic co-primary endpoints. We are deeply disappointed that the studies did not achieve their symptomatic endpoints, said Robert Alexander, CEO of Allakos. 